FOSTER CITY, CA--(Marketwire - March 01, 2010) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at three upcoming investor conferences: Rodman & Renshaw Annual China Investment Conference, Cowen Healthcare Conference, and Roth Growth Stock Conference. SciClone's executives will present a corporate overview and business update at each conference.
WHEN: Rodman & Renshaw Annual China Investment Conference
Monday, March 8; 4:05 pm Beijing time
Beijing, China
Presenter: Friedhelm Blobel, Ph.D., President and CEO
WHEN: Cowen Healthcare Conference
Tuesday, March 9; 3:45 pm ET
Boston, MA
Presenter: Gary Titus, Senior Vice President and CFO
WHEN: Roth Growth Stock Conference
Tuesday, March 16; 11:00 am PT
Laguna Niguel, CA
Presenter: Gary Titus, Senior Vice President and CFO
To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.
About SciClone
SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-focused, global
specialty pharmaceutical company with a substantial international business,
based primarily in the People's Republic of China, and with a product
portfolio of novel therapies for cancer and infectious diseases. SciClone
is focused on international sales growth, a cost-containing clinical
development strategy, and overall expense management. ZADAXIN®
(thymalfasin or thymosin alpha 1) is sold in over 30 countries for the
treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and
as a vaccine adjuvant. SciClone's pipeline of drug candidates includes
thymalfasin, in clinical studies as an enhancer of vaccines; thymalfasin
for stage IV melanoma, for which SciClone has reached agreement with the
FDA on the design of a phase 3 trial; SCV-07 in a phase 2 trial for the
delay of onset of severe oral mucositis in patients receiving
chemoradiation therapy for the treatment of cancers of the head and neck;
and SCV-07 in a phase 2 trial for the treatment of HCV. SciClone has
exclusive commercialization and distribution rights to DC Bead™ in China,
where the product is under regulatory review. The Company also has
exclusive commercialization and distribution rights to the anti-nausea drug
ondansetron RapidFilm™ in China and Vietnam, for which it will seek
regulatory approval. For additional information, please visit
www.sciclone.com.
